Across TCGA pan-cancer cohorts, LMO7DN Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LMO7DN data layer compared with 21 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LMO7DN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LMO7DN expression acts as an unfavorable survival marker.
UCEC are the cancer types where LMO7DN Mutation most reproducibly stratifies survival.